Yasuda Tomoyo, Ishikawa Takeshi, Ohta Takayuki, Yoshida Juichiro, Doi Toshifumi, Dohi Osamu, Okayama Tetsuya, Yoshida Naohisa, Kamada Kazuhiro, Uchiyama Kazuhiko, Handa Osamu, Takagi Tomohisa, Konishi Hideyuki, Shiozaki Atsushi, Fujiwara Hitoshi, Naito Yuji, Itoh Yoshito
Dept. of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science.
Gan To Kagaku Ryoho. 2018 Dec;45(12):1733-1736.
It has been reported that docetaxel, cisplatin, and 5-FU combination chemotherapy(DCF)is effective for advanced esophageal cancer. However, we often encounter severe hematotoxicity during DCF therapy. Here, we retrospectively analyzed the data of patients with advanced esophageal cancer treated with DCF at our department, and assessed the efficacy of pegfilgrastim and the issues associated with its use. According to the results, pegfilgrastim may reduce the severe hematotoxicity associated with DCF therapy and may contribute to the maintenance of the intensity of DCF. However, neutropenia had already occurred before pegfilgrastim administration on day 7 in most patients. Therefore, the appropriate timing of pegfilgrastim administration in DCF must be determined in a future prospective study.
据报道，多西他赛、顺铂和5-氟尿嘧啶联合化疗（DCF）对晚期食管癌有效。然而，我们在DCF治疗期间经常遇到严重的血液毒性。在此，我们回顾性分析了我院接受DCF治疗的晚期食管癌患者的数据，并评估了聚乙二醇化重组人粒细胞刺激因子（培非格司亭）的疗效及其使用相关问题。根据结果，培非格司亭可能会降低与DCF治疗相关的严重血液毒性，并可能有助于维持DCF的治疗强度。然而，大多数患者在第7天给予培非格司亭之前就已经出现了中性粒细胞减少。因此，必须在未来的前瞻性研究中确定DCF中培非格司亭给药的合适时机。
